Clinical trial NCT05844566 - References

Myocardial Infarction — OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

Citation(s)

•   Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P
  Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020 Oct 21;41(40):3900-3909. doi: 10.1093/eurheartj/ehaa034.
•   Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga SR, Maggioni AP, Paizis G, Tomic R, Catapano AL
  Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 Apr;271:120-127. doi: 10.1016/j.atherosclerosis.2018.02.024. Epub 2018 Feb 17.
•   Bellamy SL, Gibberd R, Hancock L, Howley P, Kennedy B, Klar N, Lipsitz S, Ryan L
  Analysis of dichotomous outcome data for community intervention studies. Stat Methods Med Res. 2000 Apr;9(2):135-59. doi: 10.1177/096228020000900205.
•   Blaum C, Seiffert M, Gossling A, Kroger F, Bay B, Lorenz T, Braetz J, Graef A, Zeller T, Schnabel R, Clemmensen P, Westermann D, Blankenberg S, Brunner FJ, Waldeyer C
  The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. Eur J Prev Cardiol. 2021 Mar 23;28(1):47-56. doi: 10.1093/eurjpc/zwaa088.
•   Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E
  Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070.
•   Campbell MJ, Donner A, Klar N
  Developments in cluster randomized trials and Statistics in Medicine. Stat Med. 2007 Jan 15;26(1):2-19. doi: 10.1002/sim.2731.
•   Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group
  Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012 Sep 4;345:e5661. doi: 10.1136/bmj.e5661. No abstract available.
•   Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ
  Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 Sep 1;2(9):959-966. doi: 10.1001/jamacardio.2017.2289.
•   Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook NR, van der Graaf Y; SMART Study Group
  Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013 Jun;99(12):866-72. doi: 10.1136/heartjnl-2013-303640. Epub 2013 Apr 10.
•   Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL
  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
•   Ferrieres J, Gorcyca K, Iorga SR, Ansell D, Steen DL
  Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice. Clin Ther. 2018 Sep;40(9):1484-1495.e22. doi: 10.1016/j.clinthera.2018.07.008. Epub 2018 Aug 18.
•   Gao F, Earnest A, Matchar DB, Campbell MJ, Machin D
  Sample size calculations for the design of cluster randomized trials: A summary of methodology. Contemp Clin Trials. 2015 May;42:41-50. doi: 10.1016/j.cct.2015.02.011. Epub 2015 Mar 9.
•   Khan I, Peterson ED, Cannon CP, Sedita LE, Edelberg JM, Ray KK
  Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. J Am Heart Assoc. 2020 Aug 4;9(15):e016506. doi: 10.1161/JAHA.120.016506. Epub 2020 Jul 28.
•   Koskinas KC, Gencer B, Nanchen D, Branca M, Carballo D, Klingenberg R, Blum MR, Carballo S, Muller O, Matter CM, Luscher TF, Rodondi N, Heg D, Wilhelm M, Raber L, Mach F, Windecker S
  Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. Eur J Prev Cardiol. 2021 Mar 23;28(1):59-65. doi: 10.1177/2047487320940102. Epub 2020 Jul 20.
•   Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, van Riemsdijk M, Herings RMC
  Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017 Apr;39(4):819-827.e1. doi: 10.1016/j.clinthera.2017.03.001. Epub 2017 Mar 27.
•   Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group
  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available. Erratum In: Eur Heart J. 2020 Nov 21;41(44):4255.
•   Mancia G, Rea F, Corrao G, Grassi G
  Two-Drug Combinations as First-Step Antihypertensive Treatment. Circ Res. 2019 Mar 29;124(7):1113-1123. doi: 10.1161/CIRCRESAHA.118.313294.
•   Marz W, Dippel FW, Theobald K, Gorcyca K, Iorga SR, Ansell D
  Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20.
•   McKay AJ, Gunn LH, Ference BA, Dorresteijn JAN, Berkelmans GFN, Visseren FLJ, Ray KK
  Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. Eur J Prev Cardiol. 2022 Mar 30;29(4):654-663. doi: 10.1093/eurjpc/zwab093.
•   Parker RA, Weir CJ
  Multiple secondary outcome analyses: precise interpretation is important. Trials. 2022 Jan 10;23(1):27. doi: 10.1186/s13063-021-05975-2.
•   Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR; DA VINCI study
  EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289. doi: 10.1093/eurjpc/zwaa047.
•   Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgozoglu LS, Connolly DL, Gerrits AJ, Stroes ESG, Masana L, Kastelein JJP
  Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022 Feb 22;43(8):830-833. doi: 10.1093/eurheartj/ehab718. No abstract available.
•   Ritz J, Spiegelman D
  Equivalence of conditional and marginal regression models for clustered and longitudinal data. Statistical Methods in Medical Research. 2004;13(4):309-323. doi:10.1191/0962280204sm368ra
•   Rubin, M
  When to adjust alpha during multiple testing: a consideration of disjunction, conjunction, and individual testing. Synthese 199, 10969-11000 (2021).
•   Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, Ueda P, James S, Reading SR, Dluzniewski PJ, Hamer AW, Jernberg T, Hagstrom E
  Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021 Jan 20;42(3):243-252. doi: 10.1093/eurheartj/ehaa1011.
•   Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK
  Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017 Feb 17;7(2):e013255. doi: 10.1136/bmjopen-2016-013255.
•   Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group
  2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. No abstract available. Erratum In: Eur Heart J. 2019 Feb 1;40(5):475.

Implementation of a Decision Support System and Its Effect on Early Optimisation of Lipid-Lowering Therapies in Patients With Acute Coronary Syndrome: a Cluster Randomised Controlled Trial

Details for clinical trial NCT05844566